Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta-analysis of randomized clinical trials
Frontiers in Oncology · 09.01.2025 · 14
DOI: 10.3389/fonc.2024.1489451 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 09.01.2025. Verfasst von Cailing Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical Univers…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of cancer worldwide and immune checkpoint inhibitors have shown favorable therapeutic effects in recurrent or metastatic or locally advanced head and neck squamous cell carcinoma (R/M/LA HNSCC). However, the effects of immunotherapy in HNSCC are still inconsistent because of complicating factors. This meta-analysis tries to provide a more precise assessment of the efficacy and safety of this integrated approach in HNSCC.
Methods
We conducted a systematic review and meta-analysis of randomized clinical trials according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. The outcomes were overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (TRAEs). A total of 8 out of 2445 articles were analyzed, including 5067 HNSCC patients, including 823 and 4244 patients with LA HNSCC and R/M HNSCC.
Results
The combined data revealed that immunotherapy has an apparent difference in OS (HR 0.86 95% CI 0.77-0.98) compared with standard of care (Soc, like fluoropyrimidine, methotrexate, docetaxel, or cetuximab) but was equal with the other treatment in PFS (HR 1.08, 95% CI 0.85-1.37). Furthermore, the occurrence of grade 3 or higher adverse events related to the drugs was lower than systematic therapy (OR 0.35, 95% CI 0.17-0.73).
Conclusions
The study has provided compelling evidence that immunotherapy is a significant benefit in OS for HNSCC patients, either R/M HNSCC or LA HNSCC, immunochemotherapy may benefit more for these patients, but double-agent immunotherapy showed no more benefit for R/M HNSCC patients. Systematic Review Registration https://www.crd.york.ac.uk/ , identifier CRD42023471570.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Zitieren
APA
Jiang, C., Wang, S., & Zhu, L. (2025). Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta-analysis of randomized clinical trials. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1489451
Vancouver
Jiang C, Wang S, Zhu L. Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta-analysis of randomized clinical trials. Frontiers in Oncology. 2025;14. doi:10.3389/fonc.2024.1489451
BibTeX
@article{Jiang2025,
author = {Jiang, Cailing and Wang, Shuqin and Zhu, Lijun},
title = {Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta-analysis of randomized clinical trials},
journal = {Frontiers in Oncology},
year = {2025},
volume = {14},
doi = {10.3389/fonc.2024.1489451}
}
EUVIMED